Novo Nordisk turns up the heat on inlicensed Genmab drug with phase III preparations

Despite the fact that Novo Nordisk has yet to publicize data from a phase II trial of hemophilia drug Mim8, which the company has developed through a license agreement with Genmab, recruitment for a future phase III study has already begun.

Photo: Novo Nordisk / PR

At Novo Nordisk, preparations are being made to begin a phase III trial of candidate Mim8, which the Danish company hopes to make a blockbuster drug – a drug expected to reach sales of over USD 1bn a year.

The preparations are being made despite the fact that Novo Nordisk has yet to present its data from a currently ongoing phase II study of the candidate. The company has previously stated that it expects results to be ready for publishing before the end of 2021.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs